Schroder Investment Management Group’s Relay Therapeutics RLAY Stock Holding History

Schroder Investment Management Group’s Portfolio RLAY Stock Details RLAY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-153,769	Closed	-$1M	–	1252
2024 Q2	$1M	Hold	153,769	–	–	﹤0.01%	1028
2024 Q1	$1.28M	Buy	+153,769	New	+$1.5M	﹤0.01%	986
2023 Q4	–	Sell	-205,420	Closed	-$1.73M	–	1262
2023 Q3	$1.73M	Sell	205,420 -15,062	-7%	-$162K	﹤0.01%	938
2023 Q2	$2.77M	Sell	220,482 -47,626	-18%	-$592K	﹤0.01%	888
2023 Q1	$4.42M	Buy	268,108 +29,866	+13%	+$536K	0.01%	811
2022 Q4	$3.56M	Buy	238,242 +90,606	+61%	+$1.73M	0.01%	841
2022 Q3	$3.3M	Sell	147,636 -23,500	-14%	-$516K	0.01%	855
2022 Q2	$2.87M	Buy	171,136 +86,491	+102%	+$1.85M	﹤0.01%	908
2022 Q1	$2.6M	Buy	+84,645	New	+$2.05M	﹤0.01%	966

Other funds holding RLAY

SIAU

SB Investment Advisers (UK) London, United Kingdom $7.73B AUM 2.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Schroder Investment Management Group's RLAY Position: Q3 2024 in Review

Schroder Investment Management Group sold out of Relay Therapeutics (RLAY) in Q3 2024, closing a stake of 153,769 shares — an estimated $1M sold.

Schroder Investment Management Group first reported a position in RLAY in Q1 2022 and held it in 9 quarters. The position peaked at $4.42M in Q1 2023. 195 funds tracked by Wall St. Rank hold RLAY as of Q3 2024.

Schroder Investment Management Group reported no remaining Relay Therapeutics position as of Q3 2024 after selling out during the quarter.
Schroder Investment Management Group sold 153,769 Relay Therapeutics shares in Q3 2024, an estimated $1M.
Schroder Investment Management Group first reported a position in Relay Therapeutics in Q1 2022 and held it in 9 quarters.
Schroder Investment Management Group's Relay Therapeutics position peaked at $4.42M in Q1 2023.
195 funds tracked by Wall St. Rank held Relay Therapeutics as of Q3 2024.

Based on Schroder Investment Management Group's 13F filing for Q3 2024, filed 13 Nov 2024.